KB Financial Partners’s Neurocrine Biosciences NBIX Stock Holding History

KB Financial Partners’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$36K	Hold	319	–	–	0.01%	293
2023 Q2	$30K	Hold	319	–	–	0.01%	325
2023 Q1	$32K	Sell	319 -45	-12%	-$4.68K	0.01%	314
2022 Q4	$43K	Sell	364 -71	-16%	-$8.32K	0.01%	276
2022 Q3	$46K	Hold	435	–	–	0.02%	254
2022 Q2	$42K	Buy	435 +43	+11%	+$3.97K	0.01%	265
2022 Q1	$37K	Hold	392	–	–	0.01%	301
2021 Q4	$33K	Buy	+392	New	+$36.1K	0.01%	331
2021 Q3	–	Sell	-397	Closed	-$39K	–	426
2021 Q2	$39K	Sell	397 -48	-11%	-$4.6K	0.01%	287
2021 Q1	$43K	Buy	+445	New	+$46.7K	0.02%	280

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

KB Financial Partners's NBIX Position: Q3 2023 in Review

KB Financial Partners held its Neurocrine Biosciences (NBIX) position steady in Q3 2023 at 319 shares worth $36K. The position accounts for 0.01% of the portfolio, ranked #293.

KB Financial Partners first reported a position in NBIX in Q1 2021 and has held it in 10 quarters since. The position peaked at $46K in Q3 2022. 511 funds tracked by Wall St. Rank hold NBIX as of Q3 2023.

KB Financial Partners held 319 shares of Neurocrine Biosciences worth $36K as of Q3 2023.
KB Financial Partners left its Neurocrine Biosciences share count unchanged in Q3 2023.
Neurocrine Biosciences made up 0.01% of KB Financial Partners's portfolio in Q3 2023, its #293 holding.
KB Financial Partners first reported a position in Neurocrine Biosciences in Q1 2021 and has held it in 10 quarters since.
KB Financial Partners's Neurocrine Biosciences position peaked at $46K in Q3 2022.
511 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2023.

Based on KB Financial Partners's 13F filing for Q3 2023, filed 15 Nov 2023.